BCAX CEO Mazumdar sells 36.8K shares for $704.7K at $19.17; stock -0.8% from 52-week high but +32.8% in 30 days
Mazumdar, as Chief Executive Officer of Bicara Therapeutics, divested 36,766 shares for $704,657.16 at $19.17 on 2026-03-09, reducing holdings by 9.8% to 339,392 shares. The sale occurred near the 52-week high ($20.06), with the current price of $19.90 only 0.8% below that peak, while the stock has surged 32.8% over the past 30 days and 5.6% over 90 days. Notably, Mazumdar's cross-ticker track record shows a 100% well-timed rate across 1 prior sell (with a 90-day return of -17.9%), and this most recent sale at BCAX represents his second transaction at this ticker following a prior sell on 2025-11-24 that also showed negative 90-day returns. Against this backdrop, the company reported a net loss of $36.3M over its most recent full fiscal year, operating at an unprofitable level with a $1.1B market cap. The timing of the sale—executed at a price near historical highs following a sharp 30-day rally—in the context of sustained operating losses, suggests the insider found current valuations appropriate for partial exit.